Results 31 to 40 of about 84,234 (301)

Olanzapine Versus Placebo in Adult Outpatients With Anorexia Nervosa: A Randomized Clinical Trial.

American Journal of Psychiatry, 2019
OBJECTIVE This study evaluated the benefits of olanzapine compared with placebo for adult outpatients with anorexia nervosa. METHODS This randomized double-blind placebo-controlled trial of adult outpatients with anorexia nervosa (N=152, 96% of whom ...
Evelyn Attia, Evelyn Attia, J. Steinglass, B. Walsh, Yuanjia Wang, Peng Wu, Colleen C. Schreyer, J. Wildes, J. Wildes, Z. Yilmaz, A. Guarda, A. Kaplan, M. Marcus   +12 more
semanticscholar   +1 more source

Hematological safety of olanzapine

Psychiatria i Psychologia Kliniczna, 2016
Olanzapine is an atypical antipsychotic medication, previously expected to be safe in terms of hematological side effects and considered an alternative choice to clozapine in patients who develop hematotoxicities.
Asem A Alageel, Eisha M Gaffas
doaj   +1 more source

Effect of adjunctive ranitidine for antipsychotic-induced weight gain: A systematic review of randomized placebo-controlled trials [PDF]

, 2017
This study was a meta-analysis of randomized controlled trials (RCTs) of ranitidine as an adjunct for antipsychotic-induced weight gain in patients with schizophrenia.
Chen, Rui, Chow, Ines, Golenkov, Andrei, Gu, Xiaojing, Li, Lu, Lok, Grace, Ng, Chee, Sun, Chen-Hui, Ungvari, Gabor S, Wang, Fei, Wang, Shi-Bin, Xiang, Yu-Tao, Yang, Xin-Hu, Zheng, Wei   +13 more
core   +3 more sources

Cost-effectiveness analysis of olanzapine in four-drug antiemetic therapy in Japanese patients treated with highly emetogenic cisplatin-containing chemotherapy

Journal of Pharmaceutical Health Care and Sciences, 2022
Background Olanzapine has been shown to have an additive effect on the three-drug antiemetic therapy consisting of aprepitant, palonosetron, and dexamethasone, in a highly emetogenic cisplatin-containing chemotherapy.
Yu Kondo, Tomoya Tachi, Takayoshi Sakakibara, Jun Kato, Takahito Mizuno, Yoshio Miyake, Hitomi Teramachi   +6 more
doaj   +1 more source

Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building. [PDF]

, 2012
A limitation in traditional stepwise population pharmacokinetic model building is the difficulty in handling interactions between model components. To address this issue, a method was previously introduced which couples NONMEM parameter estimation and ...
Belani, Chandra P, Bies, Robert R, Egorin, Merrill J, Ivy, Percy S, Lieberman, Jeffrey A, Manuck, Stephen B, Marder, Stephen R, Muldoon, Matthew F, Pollock, Bruce G, Sale, Mark E, Scher, Howard I, Sherer, Eric A, Solit, David B   +12 more
core   +3 more sources

Deep Brain Stimulation Reduces Conflict‐Related Theta and Error‐Related Negativity in Patients With Obsessive–Compulsive Disorder

Neuromodulation: Technology at the Neural Interface, EarlyView., 2021
Abstract Objectives Obsessive–compulsive disorder (OCD) is a psychiatric disorder with alterations of cortico‐striato‐thalamo‐cortical loops and impaired performance monitoring. Electrophysiological markers such as conflict‐related medial frontal theta (MFT) and error‐related negativity (ERN) may be altered by clinically effective deep brain ...
Elena Sildatke, Theo O. J. Gruendler, Markus Ullsperger, Till A. Dembek, Juan Carlos Baldermann, Sina Kohl, Veerle Visser‐Vandewalle, Daniel Huys, Jens Kuhn, Thomas Schüller   +9 more
wiley   +1 more source

Zebrafish shares common metabolic pathways with mammalian olanzapine-induced obesity

Future Journal of Pharmaceutical Sciences, 2020
Background Olanzapine is one of the most prescribed antipsychotic agents in the pharmacotherapy of psychiatric illness; however, it is associated with multiple side effects primarily obesity. Multiple investigations have been made to model the olanzapine-
Pukar Khanal, B. M. Patil, Banappa. S. Unger   +2 more
doaj   +1 more source

Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study. [PDF]

, 2015
BACKGROUND: Hospitalization is a costly and distressing event associated with relapse during schizophrenia treatment. No information is available on the predictors of psychiatric hospitalization during maintenance treatment with olanzapine long-acting ...
Ascher-Svanum, Haya, Bertsch, Jordan, Detke, Holland, Haro Abad, Josep Maria, McDonnell, David, Novick, Diego   +5 more
core   +2 more sources

Effects of olanzapine treatment on lipid profiles in patients with schizophrenia: a systematic review and meta-analysis

Scientific Reports, 2020
Olanzapine-induced dyslipidemia significantly increases the risk of cardiovascular disease in patients with schizophrenia. However, the clinical features of olanzapine-induced dyslipidemia remain hitherto unclear because of inconsistencies in the ...
Rongxing Li, Yiqi Zhang, Wenqiang Zhu, Chen Ding, W. Dai, X. Su, W. Dai, Jingmei Xiao, Zhenhua Xing, Xiansheng Huang   +9 more
semanticscholar   +1 more source

Entry of the antipsychotic drug, olanzapine, into the developing rat brain in mono- and combination therapies [version 1; peer review: 2 approved]

F1000Research, 2022
Background: Olanzapine is used to treat schizophrenia and bipolar disorder in women of childbearing age. Continuation of psychotropic medications throughout pregnancy and lactation is often required as cessation could be dangerous for both mother and ...
Mark Habgood, Katarzyna Dziegielewska, Yifan Huang, Shuai Nie, Fiona Qiu, Norman Saunders   +5 more
doaj   +1 more source